KPV Peptide Research: PepT1 Transport and Preclinical Evidence

Repair & Immune Signaling

KPV Peptide Research: PepT1 Transport and Preclinical Evidence

A readable guide to the Lys-Pro-Val tripeptide, PepT1 transport, inflammatory signaling, and the limits of cell and mouse intestinal models.

Mixed evidence4 primary sources reviewedReviewed 2026-07-29

What KPV studies show—and where translation stops

KPV is the three-amino-acid sequence Lys-Pro-Val, corresponding to residues 11–13 at the end of alpha-melanocyte-stimulating hormone. Its small size and connection to melanocortin biology make it a distinct research topic.

In intestinal cell experiments, KPV can enter through the PepT1 peptide transporter and alter NF-κB, MAP kinase, and cytokine readouts. Mouse studies have tested free KPV as well as specialized colon-targeted delivery systems.

This is a coherent preclinical story, not proof of a human anti-inflammatory treatment. Delivery method, model, and material identity must remain explicit.

What researchers are trying to understand

What is KPV?

KPV is the one-letter abbreviation for lysine-proline-valine, a tripeptide corresponding to the terminal three residues of alpha-MSH.

Why is PepT1 discussed?

PepT1 transports small peptides in intestinal models. A major cell-and-mouse paper connected PepT1 uptake of KPV with altered inflammatory signaling.

Why do delivery systems matter?

Nanoparticles and colon-targeted hydrogels change where and how a peptide is exposed. Their outcomes cannot be assigned automatically to unformulated KPV.

Notable studies, in plain English

The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.

Study 12003

KPV in crystal-induced peritonitis

Model
Mouse crystal-induced peritonitis
Design
Controlled animal inflammation study

What the paper reported: KPV reduced neutrophil accumulation and a related chemokine signal; receptor-selective comparisons informed mechanism questions.

Important limit: A mouse acute-inflammation model does not establish a human clinical effect.

Open the primary source

Study 22008

PepT1 transport and intestinal inflammatory signaling

Model
Human intestinal cell lines, a human T-cell line, and DSS/TNBS mouse colitis models
Design
In vitro transport and signaling experiments with animal validation

What the paper reported: KPV was transported by PepT1 and reduced NF-κB/MAPK activation and cytokine release in cells; inflammatory measures were lower in mouse models.

Important limit: Cell uptake and mouse outcomes do not establish human oral exposure or efficacy.

Open the primary source

Study 32008

KPV in two intestinal-inflammation models

Model
Two mouse intestinal-inflammation models, including receptor-defective mice
Design
Controlled animal mechanistic study

What the paper reported: KPV changed weight recovery, tissue inflammation, and myeloperoxidase measures; activity persisted with nonfunctional MC1 receptors.

Important limit: The results are preclinical and do not establish a human disease outcome.

Open the primary source

Study 42010

Colon-targeted KPV delivery

Model
Caco-2 intestinal cells and DSS mouse colitis
Design
Nanoparticle and hydrogel delivery study with cell and animal experiments

What the paper reported: A targeted delivery system delivered KPV to the colon and reduced experimental inflammatory and histologic measures.

Important limit: The study tested an engineered formulation, not the behavior of ordinary free KPV.

Open the primary source

What the evidence does—and does not—establish

The cited evidence does not establish clinical efficacy for inflammatory bowel disease, skin conditions, systemic inflammation, or another human condition. The central papers use cell systems and mice.

PepT1 uptake in laboratory models does not establish human oral bioavailability. Results from nanoparticles or colon-targeted hydrogels also cannot be transferred to an unformulated research vial, and alpha-MSH biology cannot be assigned wholesale to KPV.

  • KPV is the Lys-Pro-Val tripeptide derived from the alpha-MSH sequence.
  • PepT1, NF-κB, and MAPK are central preclinical research themes.
  • The cited evidence is cellular and animal, not confirmatory human evidence.
  • Formulation and delivery system materially affect interpretation.

Where to buy KPV for laboratory research in the USA

For research procurement, confirm sequence, molecular identity, lot-specific purity and method, physical form, and certificate of analysis. A product description should make clear whether the material is free KPV or part of a specialized formulation.

Commercial phrases such as buy KPV research peptide or KPV supplier USA should stay separate from human disease language. The page should not imply oral bioavailability, clinical anti-inflammatory activity, dosing, or administration.

Searches such as “where to buy KPV,” “buy KPV USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.

IdentityMatch the exact compound, sequence or blend—not just a familiar label.
FormatConfirm listed quantity, presentation and storage information before ordering.
DocumentationAsk for lot-specific records and understand what each method can actually verify.
Use restrictionsKeep research materials inside qualified laboratory workflows and applicable rules.
Available for qualified research procurementKPV

View KPV research material

KPV research FAQ

What does KPV stand for?

It is the one-letter abbreviation for lysine-proline-valine, a three-amino-acid fragment corresponding to alpha-MSH residues 11–13.

What is PepT1's role in KPV research?

In intestinal models, PepT1 transports small peptides such as KPV into cells. One major study linked that uptake to altered inflammatory signaling.

Has KPV been tested in people?

The core studies summarized here use cell systems and mouse models and do not establish human clinical benefit.

Why do KPV delivery systems matter?

Nanoparticles and colon-targeted hydrogels can change distribution and exposure, so their results cannot be assumed for free KPV.

Primary references

References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.

  1. Getting et al. (2003). PMID 12750433. DOI 10.1124/jpet.103.051623.
  2. Dalmasso et al. (2008). PMID 18061177; PMCID PMC2431115. DOI 10.1053/j.gastro.2007.10.026.
  3. Kannengiesser et al. (2008). PMID 18092346. DOI 10.1002/ibd.20334.
  4. Laroui et al. (2010). PMID 19909746. DOI 10.1053/j.gastro.2009.11.003.

Scroll to Top
0

No products in the cart.